Nesfatin-1 dosage and evidence

Sold as a weight-loss peptide, but no published study has ever given it to a person. Nobody knows what receptor it works through. All the human data just measure how much is in the blood. A review that pooled the studies in polycystic ovary syndrome (PCOS) found no difference between patients and people without PCOS at all.

Nesfatin-1 is the clearest case in this group of a compound sold ahead of its evidence. There is no evidence of any kind from giving it to people.

It is an 82-building-block piece cut from a larger protein called nucleobindin-2. In rodents, putting it into the brain makes them eat less. It does this without leptin, the body's main fullness hormone, which is why it drew interest. That result in rodents is real, repeated and reviewed.

Two facts cut against selling it.

First, nobody has pinned down the receptor it works through. That is not a small gap. Without a known receptor, you cannot design drugs for it, check what else it hits, or predict side effects. A fullness peptide with no known receptor is a research question, not a working mechanism.

Second, nobody has given it to a person. Every human record found just measures nesfatin-1 in the blood. Those studies looked at knee arthritis, endometriosis cysts, PCOS, type 2 diabetes and obesity, cord blood in babies who grew too slowly in the womb, and weight regain after weight loss. One controlled study that measured nesfatin-1 was really testing black seed (Nigella sativa) in people with Hashimoto's thyroid disease. There, nesfatin-1 was something they measured, not something they gave.

Even as a blood marker it does poorly. A review that pooled the PCOS studies found no real difference between patients and people without PCOS, 0.03 on the scale used. The studies also disagreed with each other almost completely, a disagreement score of 97.1%. That tells you something too: measurements of this peptide do not line up from one study to the next.

Nesfatin-1 has never been given to a person in a study, so there is no human evidence section on this page. That gap is the most important fact about it. We say it here instead of leaving it out quietly.

What exists is rodent work, where putting it into the brain cuts food intake. And human work that measures blood levels in different patient groups and links them to different things. Neither supports taking it.

The blood level work is weaker than it looks. When the PCOS studies were pooled in one review, the difference between patients and people without PCOS was 0.03 on the scale used. The likely range ran from minus 0.71 to plus 0.77, so it could go either way. The studies disagreed with each other almost completely, a disagreement score of 97.1%. When studies disagree that much, they are showing measurement noise at least as much as biology, and lab tests for this peptide are known to differ.

The receptor point is worth saying again because it is easy to skip. Nobody has pinned down what nesfatin-1 binds to. Every fullness claim rests on an effect seen with no known receiver. That is a fair and interesting research question. It is no basis for a product.

On money: nesfatin-1 is a natural body fragment. Nobody can own it, so no company has a reason to pay for the study that would answer any of this. The thin record is as much about money as about science. It is still a thin record, and it is still true that no person has been given this peptide in a published study.

A real test of thinking means a proper test of memory, attention, speed or planning. You take it before and after, and you are compared with a group who got a dummy and did not know it. None of the seven compounds in this group has ever been tested that way. Scores for tiredness, anxiety, hunger or a doctor's overall impression are not thinking tests. Neither is a hormone level. This matters because several of these compounds are sold for focus, clarity and mental energy, and the studies behind them measured none of those things.